Alan J. Biloski joined Johnson in July 2001 and currently oversees first-year finance majors through his leadership of the Investment Banking Immersion and his support of the practica for the Capital Markets and Asset Management and Managerial Finance Immersions. After a 15-year career in M&A banking, Biloski retired from his position as managing director of Merrill Lynch in April 2001. He had joined the firm's Healthcare Group in July 1998 and advised clients on approximately $100 billion of M&A transactions, including Pfizer's unsolicited bid for Warner Lambert, MedImmune's acquisition of US Bioscience, the sale of Mycogen to Dow Chemical, and Alkermes acquisition of Advanced Inhalation Research. In November 2000, he advised Immunex on a comprehensive restructuring of its relationship with American Home Products (now Wyeth), which included major governance changes, the dilution of AHP's ownership interest in Immunex from 55 percent to 41 percent, and the largest biotech equity offering in history, with the sale of $3.2 billion in Immunex common stock. He also led efforts that produced two of the largest private placements in biotech history, raising $160 million for Advanced Medicine (now Theravance) in 1999 and $110 million for Eyetech in 2000.
As founder of the Healthcare Group at Wasserstein Perella & Co. in 1991, Biloski assembled a group of 12 professionals, who concluded over $40 billion in pharmaceutical, health service, and medical device deals. Through his specialization in pharmaceuticals, Biloski has been responsible for a number of landmark transactions, such as SmithKline Beecham's acquisition of Sterling Winthrop (largest OTC deal), the sale of Sterling Winthrop North American to Bayer (second largest OTC deal), the sale of SmithKline Beecham's animal health business to Pfizer (largest animal health deal), SmithKline Beecham's purchase of DPS from United Healthcare (third largest pharmacy benefits manager deal), and the Chapter 11 reorganization of A. H. Robins (largest pharmaceutical product liability and bankruptcy).
Biloski is also former head of the Healthcare Mergers and Acquisitions Group at the First Boston Corporation. While there he concluded over $10 billion in healthcare M&A transactions, including the sale of A. H. Robins to American Home Products, the sale of Lyphomed to Fujisawa Pharmaceuticals, Bayer AG's purchase of Cooper Technicon, and SmithKline Beecham's acquisition of International Clinical Laboratories.
He has experience as a venture capitalist, through the Princeton, NJ firm of Johnston Associates, and as a strategic planner with Merck Sharp and Dohme Research Laboratories. Biloski also served on the board of directors of Merrill Lynch Ventures, where he had primary responsibility for evaluating new investments in the health care field.
Biloski has assisted local startups in financing their businesses, raising $15 million for Advion through Skyline and Perseus-Soros, and $7. 5 million for Gene Network Sciences. In addition, he continues to advise a small number of public and private companies on strategically important transactions. His recent assignments include advising Adolor in structuring a strategic alliance with Glaxo for the co-development and co-marketing of Alvimopan, advising Eyetech in structuring a strategic alliance with Pfizer for the co-development and co-marketing of Macugen, and advising Sagres Discovery in a merger with Chiron. During a recent 12-month exclusive advisory effort for Spectral Genomics, Inc. (SGI), Biloski renegotiated research and diagnostic licenses with Affymetrix, and subsequently conducted a comprehensive worldwide auction across 80 potential buyers. This effort culminated in a cash sale to Perkin Elmer in April 2006, at a valuation that produced a significant return for SGI's shareholders.
In December, 2007, Biloski was appointed as CEO of DNANO, a development-stage biotech company in Ithaca, New York, which is commercializing a revolutionary new cell-free process for the expression of recombinant proteins. Biloski serves as vice chairman of the board of directors of the Boyce Thompson Institute. He holds a PhD in synthetic organic chemistry from Cornell University and an MBA with distinction from Columbia University. He was elected to Phi Beta Kappa at Yale University and graduated summa cum laude with a BS/MS in Chemistry.